Naveen Pemmaraju: Superb talk on developing immune-targeting agents in AML
Naveen Pemmaraju shared on X:
“Absolutely superb talk by Dr Yasmin Abaza at AML-ALL US Focus Meeting on developing immune-targeting agents in AML!”
Source: Naveen Pemmaraju/X
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
The AML-ALL US Focus Meeting was a 3 day US focus meeting, exploring AML–ALL treatments and research at the Estancia La Jolla Hotel, from July 11-13.
